Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.

Yutaka FujiwaraYasuo TakahashiMorihito OkadaTakumi KishimotoShunsuke KondoKoshi FujikawaManabu HayamaMasatoshi SugenoShinya UedaKeiko KomuroMark LanasaTakashi Nakano

Published in: The oncologist (2022)

Tremelimumab 10 mg/kg (Q4W/Q12W), tremelimumab 1 mg/kg (Q4W) plus durvalumab 20 mg/kg (Q4W/10 mg/kg Q2W), and fixed-dose tremelimumab 75 mg (Q4W) plus durvalumab 1500 mg (Q4W) were safe and tolerable.ClinicalTrials.gov Identifier: NCT02141347 (https://clinicaltrials.gov/ct2/show/NCT02141347).

Keyphrases

computed tomography
magnetic resonance imaging
clinical trial
open label
combination therapy